This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
User:Ann Taylor/SARS-CoV2 MPro
From Proteopedia
< User:Ann Taylor(Difference between revisions)
m |
m |
||
| (6 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
==SARS-CoV2 MPro== | ==SARS-CoV2 MPro== | ||
| - | <StructureSection load='6y2e' size='340' side='right' caption='Main Protease from SARS-CoV2' scene='' | + | <StructureSection load='6y2e' size='340' side='right' caption='Main Protease from SARS-CoV2' scene=''> |
| - | Like many viruses, SARS-CoV2 synthesizes its proteins in long, polypeptide chains that must be cleaved to form functional proteins. | + | Like many viruses, SARS-CoV2 synthesizes its proteins in long, polypeptide chains that must be cleaved to form functional proteins. SARS-CoV2 uses two different proteases, a papain-like protease and the main protease. <ref> Enjuanes, L., (2005). Coronavirus replication and reverse genetics Berlin; New York: Springer, S. 69-78. </ref> While papain-like protease(s) cleave only three sites, the main protease cleaves 11 sites in the polyprotein to generate functional proteins, and is the focus of this page. |
== Overall Structure and Active Site of M protease == | == Overall Structure and Active Site of M protease == | ||
| - | The main protease is a cysteine protease that is essential for the viral life cycle. It is | + | The main protease is a cysteine protease that is essential for the viral life cycle. It is forms a <scene name='95/952725/Dimer/1'>homodimer</scene> consisting of the perpendicular protomers A and B. One protomer consists of <scene name='86/866577/Domains/2'>three domains</scene>. Domains I and II form an antiparallel chymotrypsin-like ß-barrel structure. Domain III (C-terminal end) consist of five alpha-helices arranged in an antiparallel cluster. <ref> Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G. F., Anand, K., Bartlam, M., Hilgenfeld, R. & Rao, Z. (2003). Proc Natl Acad Sci U S A. 100, 13190–13195. </ref> <ref name=”Xu”> Xu, T., Ooi, A., Lee, H. C., Wilmouth, R., Liu, D. X. & Lescar, J. (2005). Acta Crystallogr Sect F Struct Biol Cryst Commun. 61, 964–966. </ref> The substrate binds in a <scene name='95/952725/Substrate_binding_groove/1'>channel</scene> between Domains I and II. Most of the residues in the channel are neutral (shown in white) with a few acidic residues. S1 is the <scene name='95/952725/S1_with_peptide/1'>substrate binding site</scene> and consists of the side chains Phe 140, His 163 and the backbone atoms of Glu166, Asn142, Gly 143 and His172. It confers absolute specificity for the Gln-P1 substrate residue on the enzyme as the carbonyl oxygen of Gln-P1 is stabilized by interactions with the <scene name='95/952725/Oxyanion_w_substrate/1'>backbone amide</scene> groups of Gly143 and the catalytic Cys145. <ref> Gorbalenya, A. E., Snijder, E. J. & Ziebuhr, J. (2000). Journal of General Virology. 81, 853–879. </ref> <ref> Xue, X., Yu, H., Yang, H., Xue, F., Wu, Z., Shen, W., Li, J., Zhou, Z., Ding, Y., Zhao, Q., Zhang, X. C., Liao, M., Bartlam, M. & Rao, Z. (2008). Journal of Virology. 82, 2515–2527. </ref> Hence, polyproteins are cleaved within the Leu-Gln↓(Ser, Ala, Gly) sequence. <ref> Rut, W., Groborz, K., Zhang, L., Sun, X., Zmudzinski, M., Hilgenfeld, R. & Drag, M. (2020). BioRxiv. 2020.03.07.981928. </ref> |
| - | + | ||
| + | The active site involves a <scene name='86/866577/Active_site/2'>catalytic dyad</scene> consisting of the residues Cys145 and His41. It forms a covalent intermediate with the substrate in a similar fashion to a [[serine protease]]. | ||
| + | |||
| + | ==Peptidic inhibitors== | ||
| + | A number of structures of MPro with candidate inhibitors have been determined, including <scene name='42/426139/6xa4/1'>6XA4</scene>, <scene name='42/426139/6xfn/1'>6XFN</scene>, <scene name='42/426139/6xbg/1'>6XBG</scene>, <scene name='42/426139/6xbh/1'>6XBH</scene>, <scene name='42/426139/6xbi/1'>6XBI</scene>, and 6WTT. | ||
Current revision
SARS-CoV2 MPro
| |||||||||||
References
- ↑ Enjuanes, L., (2005). Coronavirus replication and reverse genetics Berlin; New York: Springer, S. 69-78.
- ↑ Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G. F., Anand, K., Bartlam, M., Hilgenfeld, R. & Rao, Z. (2003). Proc Natl Acad Sci U S A. 100, 13190–13195.
- ↑ Xu, T., Ooi, A., Lee, H. C., Wilmouth, R., Liu, D. X. & Lescar, J. (2005). Acta Crystallogr Sect F Struct Biol Cryst Commun. 61, 964–966.
- ↑ Gorbalenya, A. E., Snijder, E. J. & Ziebuhr, J. (2000). Journal of General Virology. 81, 853–879.
- ↑ Xue, X., Yu, H., Yang, H., Xue, F., Wu, Z., Shen, W., Li, J., Zhou, Z., Ding, Y., Zhao, Q., Zhang, X. C., Liao, M., Bartlam, M. & Rao, Z. (2008). Journal of Virology. 82, 2515–2527.
- ↑ Rut, W., Groborz, K., Zhang, L., Sun, X., Zmudzinski, M., Hilgenfeld, R. & Drag, M. (2020). BioRxiv. 2020.03.07.981928.
